Pamicogrel is primarily used in the development of antiplatelet therapies. It functions by inhibiting platelet aggregation, which helps prevent the formation of harmful blood clots in patients at risk of cardiovascular events. This makes it a candidate for use in treating conditions such as acute coronary syndrome and for patients undergoing percutaneous coronary interventions (PCI). Due to its targeted mechanism, it may offer improved safety profiles with reduced bleeding risks compared to other antiplatelet agents. Pamicogrel is investigated for its potential in dual antiplatelet therapy (DAPT), often in combination with other agents like aspirin, to enhance cardiovascular protection.